Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques

Blood Transfusion

Volumn 7, Issue 3, 2009, Pages 204-209

  Veneri, Dino ^a,d   Capuzzo, Enrico ^b   De Matteis, Giovanna ^a   Franchini, Massimo ^c   Baritono, Elisabetta ^a   Benati, Marco ^a   Solero, G Pietro ^a   Ambrosetti, Achille ^a   Quaresmini, Giulia ^a   Pizzolo, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Azienda Ospedaliera   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Policlinico GB Rossi   (Italy)

Author keywords

Essential thrombocythaemia; JAK2V617F mutation; Molecular diagnostic techniques

Indexed keywords

JANUS KINASE 2; JAK2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; THROMBOCYTHEMIA; AMINO ACID SUBSTITUTION; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; METHODOLOGY; MIDDLE AGED; MISSENSE MUTATION; MULTICENTER STUDY; MYELOID METAPLASIA; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIMARY MYELOFIBROSIS; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA, ESSENTIAL;

EID: 67749127756     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2009.0070-08     Document Type: Article

References (24)

1. Mertens C, Darnell JE Jr. SnapShot: JAK-STAT signaling. Cell 2007;131:612-635
2. Starr R, Hilton DJ. Negative regulation of the JAK/STAT pathway. Bioessays 1999;21:47-52.
3. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003;3:900-911
4. Levine RL, Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology 2006;1: 233-239
5. Constantinescu SN, Girardot M, Pecquet C. Links mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008;3:122-131
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148 (Pubitemid 40663494)
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397 (Pubitemid 40544655)
9. Cazzola M, Passamonti F. Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologica 2006;2:159-161 (Pubitemid 43304133)
10. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006;108:2435-2437
11. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis: impact on disease phenotype. Eur J Haematol 2007;6:508-515
12. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008;111:5109-5117
13. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092-1097 (Pubitemid 47281402)
14. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005 ; 106: 1207-1209
15. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106: 2162-2168 (Pubitemid 41291734)
16. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005;106: 2920-2921
17. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106: 3370-3373
18. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106: 3377-3379 (Pubitemid 41609169)
19. Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006;8:397-441
20. Ma W, Kantarjian H, Zhang X, et al. Higher detection rate of JAK2 mutation using plasma. Blood 2008;111:3906-3907
21. Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leuk Lymphoma 2006;47:177-194
22. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006;20:168-171
23. Xu X, Zhang Q, Luo J, et al. JAK2(V617F): prevalence in a large Chinese hospital population. Blood 2007;109:339-342
24. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-142